DESETHYLOXYBUTYNIN, HYDROCHLORIDE
| Title | Journal |
|---|---|
| Pharmacokinetics of oxybutynin chloride topical gel: effects of application site, baths, sunscreen and person-to-person transference. | Clinical drug investigation 20110101 |
| Enantioselective analysis of oxybutynin and N-desethyloxybutynin with application to an in vitro biotransformation study. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20081101 |
| The preparation and human muscarinic receptor profiling of oxybutynin and N-desethyloxybutynin enantiomers. | Medicinal chemistry (Shariqah (United Arab Emirates)) 20071101 |
| Binding activities by propiverine and its N-oxide metabolites of L-type calcium channel antagonist receptors in the rat bladder and brain. | Life sciences 20070606 |
| Pharmacokinetics/pharmacodynamics analysis of the relationship between the in vivo micturition pressure and receptor occupancy of (R)-oxybutynin and its metabolite in rats. | Biological & pharmaceutical bulletin 20070501 |
| Pharmacokinetics and pharmacodynamics of once-daily controlled-release oxybutynin and immediate-release oxybutynin. | Journal of clinical pharmacology 20070301 |
| Stereoselective pharmacokinetics of oxybutynin and N-desethyloxybutynin in vitro and in vivo. | Xenobiotica; the fate of foreign compounds in biological systems 20070101 |
| Transdermal oxybutynin in the treatment of overactive bladder. | Clinical interventions in aging 20060601 |
| Advantages for transdermal over oral oxybutynin to treat overactive bladder: Muscarinic receptor binding, plasma drug concentration, and salivary secretion. | The Journal of pharmacology and experimental therapeutics 20060301 |
| Muscarinic receptor binding, plasma concentration and inhibition of salivation after oral administration of a novel antimuscarinic agent, solifenacin succinate in mice. | British journal of pharmacology 20050501 |
| In vivo demonstration of muscarinic receptor binding activity of N-desethyl-oxybutynin, active metabolite of oxybutynin. | Life sciences 20050408 |
| [Effect of 4-ethylamino-2-butynyl(2-cyclohexyl-2-phenyl) glycolate, metabolite of oxybutynin, on intra-artery administered acetylcholine-induced urinary bladder contraction in anesthetized dogs]. | Nihon yakurigaku zasshi. Folia pharmacologica Japonica 20040501 |
| Effects of 4-ethylamino-2-butynyl(2-cyclohexyl-2-phenyl)glycolate hydrochloride, a metabolite of oxybutynin, on bladder specimens and rhythmic bladder contraction in rats in comparison with oxybutynin. | Journal of pharmacological sciences 20040201 |
| Oxybutynin extended-release: a review of its use in the management of overactive bladder. | Drugs 20040101 |
| Pharmacokinetics, metabolism, and saliva output during transdermal and extended-release oral oxybutynin administration in healthy subjects. | Mayo Clinic proceedings 20030601 |
| Sensitive determination of oxybutynin and desethyloxybutynin in dog plasma by LC-ESI/MS/MS. | Journal of pharmaceutical and biomedical analysis 20030226 |
| Transdermal oxybutynin: for overactive bladder. | Drugs & aging 20030101 |
| Transdermal oxybutynin. A viewpoint by Michael Chancellor. | Drugs & aging 20030101 |
| Transdermal oxybutynin. A viewpoint by Adrian Wagg. | Drugs & aging 20030101 |
| Binding study of desethyloxybutynin using high-performance frontal analysis method. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20020225 |
| Pharmacokinetics, efficacy, and safety of intravesical formulation of oxybutynin in patients with detrusor overactivity. | Scandinavian journal of urology and nephrology 20020201 |
| Intravesical oxybutynin: mode of action assessed by passive diffusion and electromotive administration with pharmacokinetics of oxybutynin and N-desethyl oxybutynin. | The Journal of urology 20011201 |
| Pharmacokinetics of the R- and S-enantiomers of oxybutynin and N-desethyloxybutynin following oral and transdermal administration of the racemate in healthy volunteers. | Pharmaceutical research 20010701 |